Looks like you’re on the UK site. Choose another location to see content specific to your location

Thermo Fisher’s Olink Enhances Genomic-Proteomic Integration with New Sequencing Kits
Olink, renowned for its innovative solutions in life sciences, has announced its latest advancement: next generation sequencing (NGS)-based proteomics kits designed to unify genomics and proteomics research. This release promises to streamline researchers’ work by integrating effortlessly with various existing NGS platforms, removing the need for additional specialised instruments.
The biotechnology sphere is abuzz with this development as Olink’s new kits address a significant gap in research methodologies. Traditionally, aligning genomic studies with proteomic data required substantial investment in new tools and training, often stalling progress in understanding complex biological mechanisms. By offering a flexible solution that dovetails with current NGS systems, Olink not only accelerates research timelines but also democratises access to advanced proteomic research. This strengthens collaborations across institutions and disciplines, potentially catalysing breakthroughs in understanding the roles of proteins in disease states and health.
This strategic move by Olink positions the company as a frontrunner in the biotechnological revolution, amplifying research capabilities across the life sciences domain. As researchers gear up to leverage these new kits, the landscape of genomic and proteomic research is poised for transformative advancements, fuelling innovation and potentially leading to significant discoveries in medical research and therapeutic development.
For the latest updates and in-depth insights into the world of Service Engineering, including breakthrough treatments, industry trends, and regulatory news, contact James Dolan today!
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips
and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard